Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Total Non-Current Liabilities (2016 - 2025)

Lisata Therapeutics' Total Non-Current Liabilities history spans 13 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 45.29% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 45.29%, while the annual FY2025 figure was $3.1 million, 45.29% down from the prior year.
  • Total Non-Current Liabilities reached $3.1 million in Q4 2025 per LSTA's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $6.6 million in Q4 2023 to a low of $3.1 million in Q4 2025.
  • Average Total Non-Current Liabilities over 3 years is $4.8 million, with a median of $4.6 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: rose 2.32% in 2024, then crashed 45.29% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $6.6 million in 2023, then fell by 14.83% to $5.6 million in 2024, then plummeted by 45.29% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Total Non-Current Liabilities are $3.1 million (Q4 2025), $4.6 million (Q3 2025), and $4.3 million (Q2 2025).